
Assembly Biosciences, Inc.: updates and filings
Price
$22.50
November 19, 2026Market cap $461M
What Ploutos Investor adds for Assembly Biosciences
Part of Ploutos Investor, €9.99 a month
- The full history: 10 fiscal years, from 2016
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 12, 2026next Feb 8, 2027
A rough estimate from when it has reported before, which has varied. The company announces the date itself.
November 2026
August 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 12, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 12, 2026Results of operationsForm8-K
- Aug 20, 2026Shares registered for employeesFormS-8
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 14, 2026Results of operations (amendment)Form8-K/A
- Aug 13, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 13, 2026Acquisition or disposal of assetsForm8-K
- Aug 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 4, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jun 5, 2026Officer or director change, shareholder voteForm8-K
- May 27, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- May 26, 2026Material agreement entered, other material eventsForm8-K
- May 22, 2026Regulation FD disclosure, other material eventsForm8-K
- May 11, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 7, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 7, 2026Results of operationsForm8-K
- Apr 22, 2026Additional annual meeting materialFormDEFA14A
- Apr 22, 2026Annual meeting proxy statementFormDEF 14A
- Apr 22, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Mar 30, 2026Officer or director changeForm8-K
- Mar 27, 2026FilingFormEFFECT
- Mar 25, 2026Correspondence with the SECFormCORRESP
- Mar 24, 2026Letter from the SECFormUPLOAD
- Mar 19, 2026Shelf registration for future offeringsFormS-3
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 12, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 12, 2026 | 8-K | Results of operations | Document |
| Aug 20, 2026 | S-8 | Shares registered for employees | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 14, 2026 | 8-K/A | Results of operations (amendment) | Document |
| Aug 13, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 13, 2026 | 8-K | Acquisition or disposal of assets | Document |
| Aug 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 4, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jun 5, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| May 27, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| May 26, 2026 | 8-K | Material agreement entered, other material events | Document |
| May 22, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| May 11, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 7, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 7, 2026 | 8-K | Results of operations | Document |
| Apr 22, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 22, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 22, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Mar 30, 2026 | 8-K | Officer or director change | Document |
| Mar 27, 2026 | EFFECT | Filing | Document |
| Mar 25, 2026 | CORRESP | Correspondence with the SEC | Document |
| Mar 24, 2026 | UPLOAD | Letter from the SEC | Document |
| Mar 19, 2026 | S-3 | Shelf registration for future offerings | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Feb 7, 2008.
The full analysis
What do Assembly Biosciences's filings show?
The filings are where every one of Assembly Biosciences's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.